Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice

Neuroscience Letters

Volumn 230, Issue 3, 1997, Pages 191-194

  Matsuura, Kouji ^a   Kabuto, Hideaki ^a   Makino, Hirofumi ^a   Ogawa, Norio ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

6 Hydroxydopamine; Combination treatment; Glucocorticoid; Initial cyclosporin A treatment; Monoamine concentration; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; CYCLOSPORIN A; DOPAMINE; GLUCOCORTICOID; HOMOVANILLIC ACID; HYDROCORTISONE; OXIDOPAMINE; SUCCINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG ACTIVITY; DRUG EFFICACY; EXPERIMENTAL TEST; MOUSE; NERVE CELL DEGENERATION; NERVE INJURY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RECEPTOR BINDING; TREATMENT PLANNING;

ANIMALS; CORPUS STRIATUM; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOPAMINE; GLUCOCORTICOIDS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED ICR; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; SYMPATHOLYTICS;

EID: 0030748668     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)00515-6     Document Type: Article

References (19)

1. Altar, C.A., Marien, M.R. and Marshall, J.F., Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury, J. Neurochem., 48 (1989) 390-399.
2. Bamberger, C.M., Schulte, H.M. and Chrousos, G.P., Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids, Endocr. Rev., 17 (1996) 245-261.
3. Banati, R.B., Gehrmann, J., Schubert, P. and Kreutzberg, G.W., Cytotoxicity of microglia, Glia, 7 (1993) 111-118.
4. Cadet, J.L., Katz, M., Jackson, L.V. and Fahn, S., Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence, Brain Res., 476 (1989) 10-15.
5. Clipstone, N.A. and Crabtree, G.R., Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation, Nature, 357 (1992) 695-697.
6. Cohen, G. and Heikkila, R.E., The generation of hydrogen peroxide, superoxide radical, and hydroxyradical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents, J. Biol. Chem., 249 (1974) 2447-2452.
7. Dawson, T.M., Steiner, J.P., Dawson, V.L., Dinerman, J.L., Uhl, G.R. and Snyder, S.H., Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity, Proc. Natl. Acad. Sci. USA, 90 (1993) 9808-9812.
8. Goto, S., Matsykado, Y., Mihara, Y., Inoue, N. and Miyamoto, E., The distribution of calcineurin in rat brain by light and electron microscopic immunohistochemistry and enzyme-immunoassay, Brain Res., 397 (1986) 161-172.
9. Hall, E.D., The effects of glucocorticoid and nonglucocorticoid steroids on acute neuronal degeneration, Adv. Neurol., 59 (1993) 241-248.
10. Hirsch, E.C., Does oxidative stress participate in nerve cell death in Parkinson's disease?, Eur. Neurol., 1 (1993) 52-59.
11. Kawano, T., Kazekawa, K., Nakashima, S., Kohno, H., Tanaka, N., Honma, T., Kaneko, Y. and Satoh, K., Combined drug therapy with diltiazem, dextran, and hydrocortisone (DDH therapy) for late cerebral vasospasm after aneurysmal subarachnoid hemorrhage: assessment of efficacy and safety in an open clinical study, Int. J. Clin. Pharmacol. Ther., 33 (1995) 513-517.
12. Matsuura, K., Kabuto, H., Makino, H. and Ogawa, N., Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain, Brain Res., 733 (1996) 101-104.
13. McGeer, P.L., Itagaki, S., Boyes, B.E. and McGeer, E.G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains, Neurology, 38 (1988) 1285-1291.
14. O'Regan, M.H., Smith, B.M., Perkins, L.M. and Phillis, J.W., A possible role for phospholipases in the release of neurotransmitter amino acids from ischemic rat cerebral cortex, Neurosci. Lett., 185 (1995) 191-194.
15. Ogawa, N., Levodopa and dopamine agonists in the treatment of Parkinson's disease: advantages and disadvantages, Eur. Neurol., 3 (1994) 20-28.
16. Ogawa, N., Haba, K., Asanuma, M. and Mori, A., Long-lasting effect of ceruletide on dyskinesia and monoaminergic neuronal pathways in rats treated with iminodipropionitrile, Brain Res., 556 (1991) 271-279.
17. Paliogianni, F. and Boumpas, D.T., Glucocorticoids regulate calcineurin-dependent trans-activating pathways for interleukin-2 gene transcription in human T lymphocytes, Transplantation, 59 (1995) 1333-1339.
18. Wakita, H., Tomimoto, H., Akiguchi, I. and Kimura, J., Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion, Stroke, 26 (1995) 1415-1422.
19. Walaas, S.I., Aswad, D.W. and Greengard, P., A dopamine- and cyclic AMP-regulated phosphoprotein enriched in dopamine innervated brain regions, Nature, 301 (1983) 69-71.